{"id":177557,"date":"2022-08-19T06:15:03","date_gmt":"2022-08-19T06:15:03","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=177557"},"modified":"2022-08-19T06:15:03","modified_gmt":"2022-08-19T06:15:03","slug":"stimulation-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/","title":{"rendered":"Stimulation immunotherapy"},"content":{"rendered":"

The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to increase white blood cell production in the bone marrow after cancer therapy, bone marrow transplantation, and AIDS. Erythropoietin is effective in treating anemia in patients with chronic renal failure, AIDS, and bone marrow depression following cancer therapy. Transforming growth factor beta seems to enhance wound healing and reduce fibrotic changes following inflammation. Interleukins and interferons are being studied for their beneficial effects in patients with certain leukemias and other malignant tumors. Lymphocyte-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), which are lymphocytes that have been removed from the patient and stimulated with interleukin-2, also show promise in treating malignant tumors. Monoclonal antibodies against mediators of inflammation have been created in the laboratory from hybridomas and are being studied for clinical use.<\/p>\n

\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"class_list":["post-177557","post","type-post","status-publish","format-standard","hentry","category-s"],"yoast_head":"\nStimulation immunotherapy - Definition of Stimulation immunotherapy<\/title>\n<meta name=\"description\" content=\"The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to increase white blood cell production in the bone marrow after cancer therapy, bone marrow transplantation, and AIDS. Erythropoietin is effective in treating anemia in patients with chronic renal failure, AIDS, and bone marrow depression following cancer therapy. Transforming growth factor beta seems to enhance wound healing and reduce fibrotic changes following inflammation. Interleukins and interferons are being studied for their beneficial effects in patients with certain leukemias and other malignant tumors. Lymphocyte-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), which are lymphocytes that have been removed from the patient and stimulated with interleukin-2, also show promise in treating malignant tumors. Monoclonal antibodies against mediators of inflammation have been created in the laboratory from hybridomas and are being studied for clinical use.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stimulation immunotherapy - Definition of Stimulation immunotherapy\" \/>\n<meta property=\"og:description\" content=\"The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to increase white blood cell production in the bone marrow after cancer therapy, bone marrow transplantation, and AIDS. Erythropoietin is effective in treating anemia in patients with chronic renal failure, AIDS, and bone marrow depression following cancer therapy. Transforming growth factor beta seems to enhance wound healing and reduce fibrotic changes following inflammation. Interleukins and interferons are being studied for their beneficial effects in patients with certain leukemias and other malignant tumors. Lymphocyte-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), which are lymphocytes that have been removed from the patient and stimulated with interleukin-2, also show promise in treating malignant tumors. Monoclonal antibodies against mediators of inflammation have been created in the laboratory from hybridomas and are being studied for clinical use.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-19T06:15:03+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/\",\"name\":\"Stimulation immunotherapy - Definition of Stimulation immunotherapy\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2022-08-19T06:15:03+00:00\",\"dateModified\":\"2022-08-19T06:15:03+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to increase white blood cell production in the bone marrow after cancer therapy, bone marrow transplantation, and AIDS. Erythropoietin is effective in treating anemia in patients with chronic renal failure, AIDS, and bone marrow depression following cancer therapy. Transforming growth factor beta seems to enhance wound healing and reduce fibrotic changes following inflammation. Interleukins and interferons are being studied for their beneficial effects in patients with certain leukemias and other malignant tumors. Lymphocyte-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), which are lymphocytes that have been removed from the patient and stimulated with interleukin-2, also show promise in treating malignant tumors. Monoclonal antibodies against mediators of inflammation have been created in the laboratory from hybridomas and are being studied for clinical use.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stimulation immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stimulation immunotherapy - Definition of Stimulation immunotherapy","description":"The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to increase white blood cell production in the bone marrow after cancer therapy, bone marrow transplantation, and AIDS. Erythropoietin is effective in treating anemia in patients with chronic renal failure, AIDS, and bone marrow depression following cancer therapy. Transforming growth factor beta seems to enhance wound healing and reduce fibrotic changes following inflammation. Interleukins and interferons are being studied for their beneficial effects in patients with certain leukemias and other malignant tumors. Lymphocyte-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), which are lymphocytes that have been removed from the patient and stimulated with interleukin-2, also show promise in treating malignant tumors. Monoclonal antibodies against mediators of inflammation have been created in the laboratory from hybridomas and are being studied for clinical use.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Stimulation immunotherapy - Definition of Stimulation immunotherapy","og_description":"The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to increase white blood cell production in the bone marrow after cancer therapy, bone marrow transplantation, and AIDS. Erythropoietin is effective in treating anemia in patients with chronic renal failure, AIDS, and bone marrow depression following cancer therapy. Transforming growth factor beta seems to enhance wound healing and reduce fibrotic changes following inflammation. Interleukins and interferons are being studied for their beneficial effects in patients with certain leukemias and other malignant tumors. Lymphocyte-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), which are lymphocytes that have been removed from the patient and stimulated with interleukin-2, also show promise in treating malignant tumors. Monoclonal antibodies against mediators of inflammation have been created in the laboratory from hybridomas and are being studied for clinical use.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/","og_site_name":"Glossary","article_published_time":"2022-08-19T06:15:03+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/","name":"Stimulation immunotherapy - Definition of Stimulation immunotherapy","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2022-08-19T06:15:03+00:00","dateModified":"2022-08-19T06:15:03+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"The therapeutic use of agents that stimulate immune function (immunostimulants). These agents include cytokines and cytokine antagonists, monoclonal antibodies, compounds obtained from bacteria, and hormones from the thymus. The most successful immunostimulants have been laboratory-prepared cytokines, the protein mediators of immune responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used widely to increase white blood cell production in the bone marrow after cancer therapy, bone marrow transplantation, and AIDS. Erythropoietin is effective in treating anemia in patients with chronic renal failure, AIDS, and bone marrow depression following cancer therapy. Transforming growth factor beta seems to enhance wound healing and reduce fibrotic changes following inflammation. Interleukins and interferons are being studied for their beneficial effects in patients with certain leukemias and other malignant tumors. Lymphocyte-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), which are lymphocytes that have been removed from the patient and stimulated with interleukin-2, also show promise in treating malignant tumors. Monoclonal antibodies against mediators of inflammation have been created in the laboratory from hybridomas and are being studied for clinical use.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/stimulation-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Stimulation immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/177557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=177557"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/177557\/revisions"}],"predecessor-version":[{"id":177558,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/177557\/revisions\/177558"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=177557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=177557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=177557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}